International Stem Cell Reports Progress on Primate Study, Parkinson’s Disease Cell Therapy

International Stem Cell Corporation (OTCMKTS:ISCO) reported results from the first interim analysis of the ongoing IND-enabling pharmacology/toxicology primate study: majority of the animals in this study have shown significant improvement in parkinsonism, including a return of many normal behaviors. The study is being conducted under the supervision of Professor D. Eugene Redmond Jr. MD, of Yale University Medical School.

As quoted in the press release:

“The initial data from this large controlled study is very encouraging,” said Professor Redmond. “In Parkinson’s disease research non-human primate data are considered the gold standard and are by far the best indicator of likely outcomes in humans.”

The majority of the animals in this ongoing study have shown significant improvement in parkinsonism, including a return of many normal behaviors. The study consist of 18 primates divided into three cohorts, a control group and two treatment groups with the treatment groups receiving different doses of human neural stem cells (hPNSC) derived from ISCO’s proprietary parthenogenetic stem cell line.

Click here to read the International Stem Cell Corporation (OTCMKTS:ISCO) press release